Bioray Biotech Co., Ltd (TPEX:7561)
Taiwan · Delayed Price · Currency is TWD 18.60
+0.90 (5.08%)
May 29, 2026, 11:55 AM CST
Bioray Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 222.73 | 201.71 | 191.83 | 190.6 | 148.02 | |
Revenue Growth (YoY) | 10.42% | 5.15% | 0.65% | 28.77% | -5.30% |
Cost of Revenue | 116.79 | 122.69 | 114.18 | 110.09 | 80.73 |
Gross Profit | 105.94 | 79.03 | 77.65 | 80.51 | 67.29 |
Selling, General & Admin | 43.29 | 47.66 | 52.73 | 48.48 | 53.55 |
Research & Development | 24.86 | 35.25 | 44.27 | 32.26 | 21.86 |
Operating Expenses | 68.04 | 83.34 | 96.98 | 80.82 | 75.4 |
Operating Income | 37.9 | -4.32 | -19.33 | -0.31 | -8.11 |
Interest Expense | -0.65 | -1.33 | -1.32 | -1.36 | -0.95 |
Interest & Investment Income | 1.19 | 1.27 | 0.65 | 0.19 | 0.05 |
Currency Exchange Gain (Loss) | - | 0.18 | -0.18 | -0.13 | -0.18 |
Other Non Operating Income (Expenses) | 2.8 | 5.02 | 7.09 | 2.12 | 3.02 |
EBT Excluding Unusual Items | 41.24 | 0.83 | -13.09 | 0.5 | -6.17 |
Impairment of Goodwill | - | - | -1.3 | - | - |
Gain (Loss) on Sale of Assets | - | -0.05 | 0.2 | 0.18 | - |
Other Unusual Items | - | 0.6 | - | - | - |
Pretax Income | 41.24 | 1.38 | -14.19 | 0.68 | -6.17 |
Income Tax Expense | 8.99 | 0.38 | -2.63 | 0.18 | 1.76 |
Earnings From Continuing Operations | 32.25 | 1 | -11.56 | 0.5 | -7.93 |
Minority Interest in Earnings | - | - | - | - | 0.74 |
Net Income | 32.25 | 1 | -11.56 | 0.5 | -7.19 |
Net Income to Common | 32.25 | 1 | -11.56 | 0.5 | -7.19 |
Net Income Growth | 3118.56% | - | - | - | - |
Shares Outstanding (Basic) | 30 | 30 | 30 | 28 | 27 |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 28 | 27 |
Shares Change (YoY) | -0.83% | -0.83% | 7.37% | 4.67% | 0.14% |
EPS (Basic) | 1.09 | 0.03 | -0.38 | 0.02 | -0.27 |
EPS (Diluted) | 1.09 | 0.03 | -0.38 | 0.02 | -0.27 |
EPS Growth | 3533.33% | - | - | - | - |
Free Cash Flow | 71.27 | 13.43 | -10.78 | -57.16 | -6.15 |
Free Cash Flow Per Share | 2.41 | 0.45 | -0.36 | -2.04 | -0.23 |
Dividend Per Share | - | - | - | 0.200 | - |
Gross Margin | 47.56% | 39.18% | 40.48% | 42.24% | 45.46% |
Operating Margin | 17.02% | -2.14% | -10.08% | -0.16% | -5.48% |
Profit Margin | 14.48% | 0.50% | -6.03% | 0.26% | -4.86% |
Free Cash Flow Margin | 32.00% | 6.66% | -5.62% | -29.99% | -4.15% |
EBITDA | 61.49 | 12.05 | -1.66 | 15.79 | 5.32 |
EBITDA Margin | 27.61% | 5.97% | -0.86% | 8.29% | 3.59% |
D&A For EBITDA | 23.59 | 16.37 | 17.67 | 16.11 | 13.43 |
EBIT | 37.9 | -4.32 | -19.33 | -0.31 | -8.11 |
EBIT Margin | 17.02% | -2.14% | -10.08% | -0.16% | -5.48% |
Effective Tax Rate | 21.80% | 27.39% | - | 26.69% | - |